Qilu Pharmaceutical is a vertically integrated pharmaceutical leader in China, developing, manufacturing, and marketing both APIs and finished dose forms. With 12 subsidiaries, 11 manufacturing sites, and over 39,000 employees, Qilu has launched 300+ products (including 55+ first-to-launch in China) and maintains operations across global markets.
Qilu’s therapeutic portfolio spans oncology, neurology, cardiovascular, respiratory, ophthalmology, and more, and the company supports over 5,000 scientists in R&D programs across the U.S. and China.
